Galina Karabanovich

发表

Tetrazole regioisomers in the development of nitro group-containing antitubercular agents

K. Vávrová, A. Hrabálek, O. Soukup, 2015 .

Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents.

K. Vávrová, A. Hrabálek, M. Benkova, 2017, European journal of medicinal chemistry.

Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.

P. Pávek, K. Vávrová, A. Hrabálek, 2017, Bioorganic & medicinal chemistry.

Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.

S. Cole, T. Smutny, P. Pávek, 2016, Journal of medicinal chemistry.

UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study

J. Roh, A. Jirkovská, T. Šimůnek, 2019, Scientific Reports.

One-pot synthesis of 1-substituted-5-alkylselanyl-1 H -tetrazoles from isoselenocyanates: unexpected formation of N -alkyl- N -arylcyanamides and ( Z )- Se -alkyl- N -cyano- N , N′ -diarylisoselenoureas

K. Vávrová, A. Hrabálek, J. Roh, 2013 .

Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity

N. Váňová, J. Chládek, M. Štěrba, 2021, Scientific Reports.

S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.

P. Pávek, K. Vávrová, A. Hrabálek, 2017, European journal of medicinal chemistry.

Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-D-ribofuranose 2'-Oxidase.

P. Pávek, K. Vávrová, A. Hrabálek, 2019, Journal of medicinal chemistry.

Tetrazoles: LV. Perparation of 2-anilino-5-aryl(hetaryl)-1,3,4-oxadiazoles from 5-substituted tetrazoles under microwave activation

T. V. Artamonova, G. I. Koldobskii, Galina Karabanovich, 2009 .

Microwave-assisted synthesis of 2-aryl(hetaryl)-5-phenylamino-1,3,4-thiadiazoles from 5-substituted tetrazoles

T. V. Artamonova, G. I. Koldobskii, Galina Karabanovich, 2009 .

One‐Pot Synthesis of 1‐Substituted‐5‐alkylselanyl‐1H‐tetrazoles from Isoselenocyanates: Unexpected Formation of N‐Alkyl‐N‐arylcyanamides and (Z)‐Se‐Alkyl‐N‐cyano‐N,N′‐diarylisoselenoureas.

K. Vávrová, A. Hrabálek, J. Roh, 2014 .

1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.

T. Smutny, P. Pávek, K. Vávrová, 2014, European journal of medicinal chemistry.

Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity

M. Štěrba, J. Kubeš, M. Adamcová, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation

A. Lyon, M. Štěrba, J. Kubeš, 2021, Circulation. Heart failure.

Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart

J. Chládek, M. Štěrba, J. Bureš, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity on a rabbit model in vivo.

N. Váňová, M. Štěrba, J. Kubeš, 2021, Clinical science.

Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer’s Disease

O. Soukup, L. Prchal, A. Misiachna, 2023, International journal of molecular sciences.

UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study

J. Roh, A. Jirkovská, T. Šimůnek, 2019, Scientific Reports.

Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.

M. Štěrba, J. Bureš, J. Roh, 2017, Toxicology.

Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage

Lenka Applová, M. Štěrba, J. Roh, 2024, Toxicological sciences : an official journal of the Society of Toxicology.